Increased ROS production is cardiotoxic.
Link: A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers - PMC (nih.gov)
Link: Frontiers | Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells (frontiersin.org)
Link: Understanding of ROS-Inducing Strategy in Anticancer Therapy (hindawi.com)
Clofarabine has a slight increase in ROS and cardiotoxicity.
Where am I going with the above, will Sheba 2.0 there were no adverse cardiac events. Is this coincidence or the result of cardio protection. Is Bisantrene able to shield healthy cells from excessive ROS production, whilst allowing ROS overload to continue to kill cancer cells? If so, this is a delicate balance and would be hard to replicate.
Ann: Race Board and Management Team Changes, page-451
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.010(0.63%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.56 | $168.3K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |